arrow
K

Karen Willard-Gallo

irccs ca granda ospedale maggiore policlinico
H指数:48
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy

新辅助FOLFIRINOX治疗后序贯高剂量立体定向体部放疗对胰腺导管腺癌有利的组织-分子重塑

2026-01-050
OAAI
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study

Palbociclib和内分泌疗法减弱早期乳腺癌的适应性抗肿瘤免疫:NeoRHEA 2期研究

2025-11-260
OAAI
Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial

在难治性晚期黑色素瘤患者中,通过瘤内(IT)途径给予自体CD1c(BDCA-1)+/CD141(BDCA-3)+髓样树突状细胞(myDC),联合免疫佐剂AS01B、ipilimumab(IPI)以及静脉注射nivolumab(NIVO):一项 Ib 期临床试验

2024-09-010
PRE
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab

免疫治疗生物标志物的漫长而曲折的道路: 对使用pembrolizumab治疗的三阴性乳腺癌患者样本的回顾性分析

2024-05-010
OAAI
A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma

在患有肾癌的患者中使用Nivolumab和Cabozantinib联合治疗后发生的肝消失胆管综合征的罕见病例

2022-02-195
OA
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

TILs在乳腺癌中的故事: 国际免疫肿瘤学生物标志物工作组的报告

2021-12-01146
OA
Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity
2021-10-01101
OA
Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment

荧光多重免疫组织化学与其他最先进的技术相结合,以系统地表征肿瘤免疫微环境

2021-09-2119
OAAI
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors
2021-06-2350
OAAI
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+T cells
2020-12-1053
OAAI